Notable Labs, LTD 8-K filings

Notable Labs, Ltd. will be delisted from the Nasdaq Stock Market after filing for Chapter 7 bankruptcy.

Notable Labs, Ltd. and its subsidiaries have filed for Chapter 7 bankruptcy, leading to the resignation of the board of directors and termination of key executives.

Notable Labs is exploring strategic alternatives, pausing a Phase 2 clinical trial, and reducing its workforce by approximately 65% to conserve cash.

Notable Labs has appointed Kaile A. Zagger as its Interim Chief Executive Officer and Chief Restructuring Officer, effective September 16, 2024.

Notable Labs has announced the resignation of its CEO, Thomas Bock, and the appointment of Joseph Wagner as interim CEO, while affirming plans to initiate a Phase 2 program for volasertib.

Notable Labs has released a white paper detailing the design of its Phase 2 trial for Volasertib in relapsed/refractory Acute Myeloid Leukemia (AML), incorporating enhanced antibiotic prophylaxis, tailored dosing, and its Predictive Medicine Platform.

Notable Labs has received FDA clearance and agreed on a dosing plan for its Phase 2 clinical trial of volasertib for relapsed refractory acute myeloid leukemia, paving the way for patient enrollment.

Notable Labs has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement and has until January 13, 2025, to regain compliance.

Notable Labs, Ltd. released an updated business overview slide presentation on May 30, 2024.

Notable Labs, Ltd. released a business overview slide presentation on May 6, 2024, providing an update on the company's activities.

Notable Labs announced its 2023 financial results, highlighting progress in its clinical programs and the use of its Predictive Precision Medicine Platform.

Notable Labs announced the design of its Phase 2 trial for volasertib in relapsed/refractory AML, incorporating its Predictive Precision Medicine Platform (PPMP) to identify likely responders.

Notable Labs presented data at AACR 2024 demonstrating the successful use of cryopreserved samples in their Predictive Precision Medicine Platform (PPMP), potentially broadening its application.

Notable Labs shareholders approved a new employee share plan, amended CEO compensation, appointed a new auditor, and approved a director and officer compensation policy at a special meeting on March 22, 2024.

Notable Labs, Ltd. has dismissed Deloitte & Touche LLP as its independent registered public accounting firm, effective March 21, 2024, following a recent merger.

Notable Labs is advancing its volasertib Phase 2 program for relapsed/refractory acute myeloid leukemia, utilizing its Predictive Precision Medicine Platform to improve patient outcomes and reduce development costs.

Notable Labs has dismissed Kesselman & Kesselman as its independent auditor and engaged WithumSmith+Brown, effective January 30, 2024.